-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Abvc Biopharma, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2018 to Q1 2022.
- Abvc Biopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2022 was -$86.9K, a 70.2% decline year-over-year.
- Abvc Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $116K, a 86.6% decline from 2022.
- Abvc Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $865K, a 4.93% increase from 2021.
- Abvc Biopharma, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $824K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)